查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1735648

被忽視的熱帶疾病藥物和疫苗的全球市場規模（按產品、疾病、地區和預測）

Global Neglected Tropical Diseases Drugs And Vaccines Market Size By Product (Drugs, Vaccines), By Disease (Lymphatic Filariasis, Echinococcosis, Leishmaniasis, Dracunculiasis, Dengue, Chikungunya), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

被忽視的熱帶疾病治療和疫苗的市場規模和預測

被忽視的熱帶疾病（NTD）治療和疫苗的市場規模近年來一直以中等速度成長，成長率顯著，預計在市場估計和預測期（2026年至2032年）內將大幅成長。

  • 被忽視的熱帶疾病 (NTD) 治療和疫苗是專門設計用於預防、治療或消除主要影響衛生資源有限的熱帶和亞熱帶地區人民的疾病的藥物和免疫接種。
  • 瘧疾、登革熱、利什曼原蟲症和血吸蟲病是影響全球數百萬人的疾病之一，其中大多數人生活在低收入國家。
  • NTD 藥物旨在治療由多種病原體引起的感染疾病，而疫苗旨在激活免疫系統並預防這些疾病的發生。
  • 此外，這些治療方法針對的是那些通常比流行感染疾病受到較少關注和資金支持的疾病，在全球衛生計劃中發揮著重要作用，從而促進了全球範圍內健康差距的縮小和醫療保健機會的公平性。

全球被忽視的熱帶疾病藥物和疫苗市場動態

影響被忽視的熱帶疾病藥物和疫苗市場的關鍵市場動態是：

關鍵市場促進因素

  • 全球健康計劃和增加資金籌措：由世界衛生組織、蓋茲基金會和其他非政府組織主導的全球健康計劃正在增加對NTD研究和開發的資金和支持，旨在透過提供所需的治療和疫苗來根除或控制某些疾病，從而推動市場發展。
  • 研發技術進步：生物技術和遺傳學的進步正在加速NTD治療方法和疫苗的研發。先進技術的運用正在加速新治療方法和疫苗的研發，從而推動市場成長。
  • 提升認知度和政府支持：全球對被忽視熱帶疾病的認知度正在不斷提升，各國政府和國際組織對抗擊被忽視熱帶疾病的支持也不斷增加。旨在預防、控制和消除被忽視熱帶疾病的國家衛生計畫和政策正在推動對可行治療方案的需求。
  • 合作與夥伴關係：政府、製藥公司和非營利組織之間的策略合作對於NTD治療和疫苗的開發和推廣至關重要。這些合作改善了研究、資金籌措和治療的可近性，從而顯著促進了市場成長。

主要挑戰

  • 製藥公司財政獎勵有限：由於被忽視的熱帶疾病主要影響欠低度開發國家的低收入人群，製藥公司幾乎沒有商業性獎勵投資研發。這種財政誘因的缺乏阻礙了創新有效藥物的開發。
  • 複雜的藥物研發流程：針對被忽視的熱帶疾病 (NTD) 的藥物和疫苗研發流程複雜、成本高昂且耗時。挑戰包括需要進行大規模臨床研究、獲得監管部門的核准，以及在受這些疾病影響最嚴重的地區進行研究的難度，所有這些都影響著市場的成長。
  • 分發和獲取挑戰：在偏遠貧困地區分發有效藥物和疫苗是一個主要問題。基礎設施薄弱、醫療機構匱乏以及政治不穩定，可能會阻礙需要治療的人獲得治療，從而限制現有解決方案的有效性。

主要趨勢：

  • 加強官民合作關係關係 (PPP)：政府、私人企業和非營利組織之間的合作日益增加。這些合作充分利用了各自領域的優勢，加快了被忽視的熱帶疾病 (NTD) 藥物和疫苗的資金籌措、研發和分發，並促進了市場成長和宣傳。
  • 重點在於疫苗研發：鑑於疫苗的預防特性和成本效益，人們越來越重視NTD疫苗的研究。 mRNA疫苗和重組疫苗等疫苗技術創新正在被研究用於預防這些疾病，並代表該領域的主要趨勢。
  • 全球衛生計劃協助提升可近性：全球衛生計畫日益重視提高被忽視的熱帶疾病（NTD）治療和疫苗接種的可近性。為了最大限度地減輕被忽視的熱帶疾病（NTD）的全球負擔，各方正在努力協商降低成本、加強供應鏈，並改善流行地區的醫療設施，這將影響市場動態。

目錄

第1章 全球被忽視的熱帶疾病藥物及疫苗市場介紹

  • 市場概覽
  • 研究範圍
  • 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

第4章被忽視的熱帶疾病藥物和疫苗的全球市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

第5章全球被忽視的熱帶疾病藥物和疫苗市場（按產品）

  • 概述
  • 製藥
  • 疫苗

第6章全球被忽視的熱帶疾病藥物和疫苗市場（按疾病）

  • 概述
  • 淋巴絲蟲病
  • 包蟲病
  • 利什曼原蟲症
  • 蜻蜓病
  • 登革熱
  • 屈公病
  • 其他

7. 全球被忽視的熱帶疾病藥物和疫苗市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 世界其他地區
    • 拉丁美洲
    • 中東和非洲

第8章全球被忽視的熱帶疾病藥物和疫苗市場的競爭格局

  • 概述
  • 各公司市場排名
  • 主要發展策略

第9章 公司簡介

  • Johnson & Johnson
  • GlaxoSmithKline
  • Sanofi
  • Novartis
  • Bayer
  • Eli Lilly and Company
  • Pfizer
  • AbbVie Inc.
  • Amgen Inc.
  • Gilead Sciences Inc.

第10章 重大進展

  • 產品發布/開發
  • 合併與收購
  • 業務擴展
  • 夥伴關係與合作

第11章 附錄

  • 相關調查
簡介目錄
Product Code: 35774

Neglected Tropical Diseases Drugs And Vaccines Market Size And Forecast

The Neglected Tropical Diseases Drugs And Vaccines Market size is growing at a moderate pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e.2026 to 2032.

  • Neglected Tropical Diseases (NTD) Drugs and vaccines are pharmaceuticals and vaccinations specifically designed to prevent, treat, or eradicate diseases that primarily affect populations in tropical and subtropical regions with limited access to healthcare resources.
  • Malaria, dengue fever, leishmaniasis, and schistosomiasis are among the diseases that affect millions of people globally, with the majority of them living in low-income nations.
  • NTD medicines are intended to treat infections caused by numerous pathogens, whilst vaccines attempt to activate the immune system and prevent the onset of these diseases.
  • Furthermore, these interventions play an important role in global health initiatives by targeting diseases that generally receive less attention and financing than more prominent infectious diseases, thereby reducing health inequities and promoting fairness in healthcare access on a worldwide scale.

Global Neglected Tropical Diseases Drugs And Vaccines Market Dynamics

The key market dynamics that are shaping the Neglected Tropical Diseases Drugs And Vaccines Market include:

Key Market Drivers

  • Increased Global Health Initiatives and Funding: Global health initiatives led by WHO, the Gates Foundation, and other non-governmental organizations have expanded financing and support for NTD research and development. This support seeks to eliminate or control certain diseases by supplying required treatments and vaccines, hence driving the market.
  • Technological Advancements in Research and Development: Advances in biotechnology and genetics have accelerated the discovery of treatments and vaccines for NTDs. The use of advanced techniques accelerates the discovery of novel treatment approaches and vaccines, driving market growth.
  • Rising Awareness and Government Support: There is an increasing global awareness of NTDs, which has led to increased government and international assistance for combating these diseases. National health programs and policies aimed at NTD prevention, control, and elimination promote the need for viable treatment solutions.
  • Collaborations and Partnerships: Strategic alliances among governments, pharmaceutical corporations, and non-profit groups are critical for the development and delivery of NTD treatments and vaccines. These alliances make research, funding, and therapy more accessible, hence contributing considerably to market growth.

Key Challenges:

  • Limited Financial Incentives for Pharmaceutical Companies: Neglected Tropical Diseases primarily affect low-income populations in underdeveloped nations, providing few commercial incentives for pharmaceutical corporations to invest in R&D. This lack of financial motive hampers the development of innovative and effective medicines.
  • Complex Drug Development Process: The drug and vaccine development process for NTDs is complicated, expensive, and time-consuming. Challenges include the requirement for extensive clinical studies, regulatory approvals, and the difficulty of doing research in the regions most impacted by these diseases, all of which impact market growth.
  • Distribution and Access Challenges: Effective medicine and vaccine distribution in remote and poor locations is a major concern. Poor infrastructure, a lack of healthcare facilities, and political instability make treatments inaccessible to individuals in need, limiting the effectiveness of available solutions.

Key Trends:

  • Increased Use of Public-Private Partnerships (PPPs): Collaborations between governments, commercial sector entities, and non-profit groups are increasing. These collaborations use the strengths of each sector to increase funding, research, and distribution efforts for NTD medications and vaccines, hence improving market growth and outreach.
  • Focus on Vaccine Development: Given vaccines' preventive nature and cost-effectiveness, there is a growing emphasis on NTD vaccine research. Innovations in vaccine technology, such as mRNA and recombinant vaccines, are being investigated to prevent these diseases, indicating a significant trend in the field.
  • Expanding Access Through Global Health Initiatives: Global health programs are increasingly focusing on improving access to NTD treatments and vaccinations. Efforts to negotiate lower costs, strengthen supply chains, and improve healthcare facilities in impacted areas aim to minimize the worldwide burden of NTDs, which will shape market dynamics.

Global Neglected Tropical Diseases Drugs And Vaccines Market Regional Analysis

Here is a more detailed regional analysis of the Neglected Tropical Diseases Drugs And Vaccines Market:

Asia Pacific:

  • According to VMR Analyst, Asia Pacific is estimated to dominate the Neglected Tropical Diseases Drugs And Vaccines Market during the forecast period. A large proportion of the global population is affected by Neglected Tropical Diseases (NTDs) in Asia Pacific. The high prevalence of these diseases in the region generates a need for effective treatments and vaccines, establishing Asia Pacific as a critical market for NTD therapies.
  • Governments and private sectors in the Asia-Pacific region are investing more in healthcare infrastructure and services. This includes major investment in NTD prevention, treatment, and eradication, which will help to boost the region's medication and vaccine markets.
  • The region has emerged as a hotspot for collaborative R&D initiatives aimed at NTDs, with partnerships comprising local governments, international health organizations, and pharmaceutical corporations. These agreements improve the development and availability of new therapies and vaccinations.
  • Furthermore, in Asia Pacific countries, improvements in healthcare access and delivery systems have made it easier to distribute and administer NTD treatments and vaccines. Enhanced healthcare infrastructure and higher healthcare spending help to explain the region's dominance in the NTD medicines and vaccines market.

Latin America:

  • In Latin America, governments and non-governmental organizations (NGOs) have launched comprehensive efforts to control and eliminate NTDs. These initiatives include mass drug administration campaigns and vaccination drives, which have considerably increased the demand for NTD-related pharmaceuticals and vaccines in the region.
  • Latin America benefits from international financing and cooperation to tackle NTDs. Global health organizations such as PAHO, WHO, and the Gates Foundation provide critical financial and technical support for medicine and vaccine research, development, and distribution, hence boosting market growth.
  • Latin America has experienced a surge in regional collaboration on NTD research and development. Consortia of local research institutions, universities, and pharmaceutical businesses are developing creative methods to combat NTDs, promoting local market growth.
  • Furthermore, the region's healthcare infrastructure and services are improving significantly, making it easier to deliver NTD treatments and vaccines. Improved healthcare systems, as well as increased healthcare access in rural and underprivileged areas, are significant drivers of Latin America's growing market for NTD interventions.

Middle East & Africa:

  • Due to socioeconomic and climatic variables, the Middle East and Africa (MEA) region has a high incidence of neglected tropical diseases. The high prevalence of NTDs creates an urgent need for effective medications and vaccines, accelerating market growth in this region.
  • MEA governments, with the backing of international health organizations, are increasingly focused on NTD control and elimination programs. These activities frequently include mass drug administration and immunization campaigns, which directly increase demand for NTD-related drugs.
  • Healthcare investments in the MEA region have increased significantly, with an emphasis on enhancing infrastructure and access. This includes investments in hospitals, clinics, and distribution networks for medications and vaccinations, which will expand the reach and impact of NTD interventions.
  • Furthermore, MEA countries and worldwide partners are collaborating to promote NTD research and development. These collaborations seek to develop and implement effective treatments and vaccinations adapted to the region's specific needs, hence promoting the growth of the NTD medications and vaccines market.

Global Neglected Tropical Diseases Drugs And Vaccines Market: Segmentation Analysis

The Global Neglected Tropical Diseases Drugs And Vaccines Market is segmented based on Product, Disease, And Geography.

Neglected Tropical Diseases Drugs And Vaccines Market, By Product

  • Drugs
  • Vaccines

Based on Product, the market is segmented into Drugs and Vaccines. The drugs segment is estimated to dominate the Neglected Tropical Diseases Drugs And Vaccines Market due to the acute requirement for therapy in affected people, medications are the primary intervention approach. Drugs are utilized not only for treatment but also for preventative chemotherapy in high-risk populations, which can be implemented faster than vaccine development and distribution. Furthermore, the wider choice of accessible pharmacological therapies for numerous NTDs, as opposed to vaccinations, which are only available for a few diseases, contributes to pharmaceuticals' bigger market share.

Neglected Tropical Diseases Drugs And Vaccines Market, By Disease

  • Lymphatic Filariasis
  • Echinococcosis
  • Leishmaniasis
  • Dracunculiasis
  • Dengue
  • Chikungunya
  • Others

Based on Disease, the market is segmented into Lymphatic Filariasis, Echinococcosis, Leishmaniasis, Dracunculiasis, Dengue, Chikungunya, and Others. The Dengue disease segment is estimated to hold the majority share in the forecast period in the Neglected Tropical Diseases Drugs And Vaccines Market owing to dengue fever's extensive prevalence in tropical and subtropical locations around the world, which affects millions of people each year. The disease's high occurrence rate, combined with the serious health issues it can bring, necessitates extensive research and development efforts for effective dengue vaccines and therapeutic medications. Furthermore, increasing public health initiatives and financing targeted at preventing dengue transmission, such as large-scale vaccination campaigns and community awareness programs, add to the need for dengue-related pharmaceutical products.

Key Players

  • The "Neglected Tropical Diseases Drugs And Vaccines Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Johnson & Johnson, GlaxoSmithKline, Sanofi, Merck & Co., Novartis, Bayer, Eli Lilly and Company, Pfizer, AbbVie Inc., Amgen Inc., Gilead Sciences Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., and Roche Diagnostics International Ltd.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • Global Neglected Tropical Diseases Drugs And Vaccines Market Recent Developments
  • In March 2024, the World Health Organization (WHO) emphasized African health ministers' commitment to eliminating malaria deaths. This represents a larger effort to control diseases that frequently overlap with neglected tropical diseases, even if it is not a direct NTD medicine or vaccine.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET, BY PRODUCT

  • 5.1 Overview
  • 5.2 Drugs
  • 5.3 Vaccines

6 GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET, BY DISEASE

  • 6.1 Overview
  • 6.2 Lymphatic Filariasis
  • 6.3 Echinococcosis
  • 6.4 Leishmaniasis
  • 6.5 Dracunculiasis
  • 6.6 Dengue
  • 6.7 Chikungunya
  • 6.8 Others

7 GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East and Africa

8 GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 Johnson & Johnson
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 GlaxoSmithKline
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Sanofi
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Novartis
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Bayer
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Eli Lilly and Company
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 Pfizer
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 AbbVie Inc.
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Amgen Inc.
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments
  • 9.10 Gilead Sciences Inc.
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments

10 KEY DEVELOPMENTS

  • 10.1 Product Launches/Developments
  • 10.2 Mergers and Acquisitions
  • 10.3 Business Expansions
  • 10.4 Partnerships and Collaborations

11 Appendix

  • 11.1 Related Research